Kinase inhibitors - living meta-analysis of clinical studies

table network network 2

demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only

	COVID-19 mild to moderate	COVID-19 severe or critically

	COVID 19 hospitalized	COVID-19 mild to moderate	COVID-19 severe or critically
Kinase inhibitors
acalabrutinib	CALAVI US CALAVI
imatinib		Covid-19 HUF	Aman

1 studies excluded by filtering options 1

6323

Roschewski, 2020

2

99

0

excluded

not a RCT

risk of bias not avaialble